Is Buying Theravance Biopharma Inc – Ordinary Shares (NASDAQ:TBPH), Having Higher Short Interest a Winning Strategy?

July 13, 2018 - By Robert Reynolds

Theravance Biopharma, Inc. (NASDAQ:TBPH) Logo

Investors sentiment increased to 1.35 in Q1 2018. Its up 0.04, from 1.31 in 2017Q4. It increased, as 6 investors sold Theravance Biopharma, Inc. shares while 25 reduced holdings. 14 funds opened positions while 28 raised stakes. 35.61 million shares or 1.57% more from 35.06 million shares in 2017Q4 were reported.
Legal And General Grp Public Lc owns 14,881 shares. Qs Investors Ltd Co owns 2,500 shares. New York-based Bnp Paribas Arbitrage has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Whittier Tru Company has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Tiaa Cref Mngmt Ltd Co holds 124,812 shares or 0% of its portfolio. Pictet Asset Mgmt has invested 0.01% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Bank Of Montreal Can owns 6,210 shares. Group Incorporated One Trading Limited Partnership holds 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 1,100 shares. Rock Springs Cap Mgmt L P holds 0.68% or 652,600 shares in its portfolio. Jacobs Levy Equity Mgmt stated it has 0.03% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). Savings Bank Of Mellon holds 0% or 209,907 shares. Dekabank Deutsche Girozentrale holds 24,000 shares or 0% of its portfolio. Schwab Charles Invest holds 0% or 209,075 shares. Swiss Bank & Trust holds 0% or 75,142 shares in its portfolio. Moreover, California Employees Retirement has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH).

Since May 18, 2018, it had 1 buying transaction, and 2 sales for $556,864 activity. GALA RENEE D also sold $242,877 worth of Theravance Biopharma, Inc. (NASDAQ:TBPH) shares. MALKIEL BURTON G had bought 1,000 shares worth $22,540.

The stock of Theravance Biopharma Inc – Ordinary Shares (NASDAQ:TBPH) registered an increase of 0.4% in short interest. TBPH’s total short interest was 6.29 million shares in July as published by FINRA. Its up 0.4% from 6.27M shares, reported previously. With 254,400 shares average volume, it will take short sellers 25 days to cover their TBPH’s short positions. The short interest to Theravance Biopharma Inc – Ordinary Shares’s float is 19.35%.

The stock decreased 0.87% or $0.23 during the last trading session, reaching $26.27. About 62,508 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has declined 36.55% since July 13, 2017 and is downtrending. It has underperformed by 49.12% the S&P500.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.44 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

Among 3 analysts covering Theravance Biopharma (NASDAQ:TBPH), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Theravance Biopharma had 4 analyst reports since February 8, 2018 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, May 8. The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) earned “Buy” rating by Cantor Fitzgerald on Tuesday, February 27. On Thursday, February 8 the stock rating was maintained by Leerink Swann with “Outperform”. Piper Jaffray initiated the stock with “Buy” rating in Thursday, March 29 report.

Another recent and important Theravance Biopharma, Inc. (NASDAQ:TBPH) news was published by 247Wallst.com which published an article titled: “Major Biopharma Catalysts on July’s FDA Calendar” on July 07, 2018.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.